CoChat
Sign Up
Cited by 417RNA Interference and Gene DeliveryDNA and Nucleic Acid ChemistryRNA Research and Splicing

The DOI matches its Crossref record; 241 of the 243 references it cites were found in a registry or an index.

Progress in Antisense Technology

Crooke, Stanley T.·2004·Annual Review of Medicine
DOI 10.1146/annurev.med.55.091902.104408
Open this paper in CoChat — free account

Abstract

Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.

Overview

Integrity signals

Registry

Crossref · 10.1146/annurev.med.55.091902.104408

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–241 of 241

Research works printed but not linked: 39

  1. Crouch RJ, 1985, Nucleases, 211
  2. Morvan F, 1991, Anticancer Drug Des., 6, 521
  3. Mirabelli CK, 1991, Anti-Cancer Drug Design, 6, 647
  4. 42. Cohen JS. 1993. Phosphorothioate oligodeoxynucleotides. See Ref.42a, pp.205–22
  5. Crooke ST, 1996, J. Pharmacol. Exp. Ther., 277, 923
  6. Joos RW, 1969, J. Pharmacol. Exp. Ther., 166, 113
  7. Crooke RM, 1995, J. Pharmacol. Exp. Ther., 275, 462
  8. Gao W-Y, 1992, Mol. Pharmacol., 41, 223
  9. Stein CA, 1991, J. Acquired Immune Deficiency Syndromes, 4, 686
  10. Cossum PA, 1993, J. Pharmacol. Exp. Ther., 267, 1181
  11. Crooke ST, 1993, Curr. Opin. Invest. Drugs, 2, 1045
  12. Sands H, 1995, Mol. Pharmacol., 47, 636
  13. Crooke RM, 1991, Anti-Cancer Drug Design, 6, 609
  14. 67. Crooke RM. 1993. in vitro and in vivo toxicology of first generation analogs. See Ref.42a, pp.471–92
  15. Bennett CF, 1992, Mol. Pharmacol., 41, 1023
  16. Iversen P, 1992, Anticancer Drug Des., 6, 531
  17. Cossum PA, 1994, J. Pharmacol. Exp. Ther., 269, 89
  18. 10.1038/clpt.1994.189 · DOI
  19. Butler M, 1997, Lab. Invest., 77, 379
  20. Sands H, 1994, Mol. Pharmacol., 45, 932
  21. Graham MJ, 1998, J. Pharmacol. Exp. Ther., 286, 447
  22. 95. Mirabelli CK, Crooke ST. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
  23. 103. Crooke ST, Mirabelli CK. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
  24. Zhang S-P, 1994, J. Pharmacol. Exp. Ther., 271, 1462
  25. Dean N, 1996, Cancer Res., 56, 3499
  26. Maksymowych W, 1999, Arthritis Rheumatol., 42, S170
  27. O'Dwyer PJ, 1999, Clin. Cancer Res., 5, 3977
  28. Henry SP, 1997, J. Pharmacol. Exp. Ther., 281, 810
  29. Cornish KG, 1993, Pharmacol.Comm., 3, 239
  30. Henry SP, 1997, Anti-Cancer Drug Des., 12, 395
  31. Wallace TL, 1996, J. Pharmacol. Exp. Ther., 278, 1306
  32. Henry S, 1994, Pharm. Res., 11, S-353/S1-S490
  33. Lemonidis-Farrar K, 2000, Toxicologist, 42, 120
  34. Yuen AR, 1999, Clin. Cancer Res., 5, 3357
  35. 164. Crooke ST. 2001. Basic principles. See Ref.46a, pp.1–28
  36. Zellweger T, 2001, J. Pharmacol. Exp. Ther., 298, 1
  37. Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 898
  38. Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 890
  39. Henry SP, 2000, J. Pharmacol. Exp. Ther., 292, 468

Cited by

Sorted by citations

See all 417

Related

See all

Metadata

Authors
Crooke, S. T.
Affiliations
Ionis Pharmaceuticals (United States) (US)
Corresponding author
Crooke, Stanley T.
ORCID
Crooke, Stanley T.
Venue
Annual Review of Medicine
Publisher
Annual Reviews
Published
2004-02-01
Volume
55
Issue
1
Pages
61-95
ISSN
  • 0066-4219 (ISSN-L)
  • 1545-326X
DOI
10.1146/annurev.med.55.091902.104408
OpenAlex
W2138668121
Cited by
417
References
243
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 24 · 2012: 32
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Locations
  • Annual Review of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords
antisense technology, oligonucleotide analogues, RNA hybridization, RNA degradation, RNA splicing, antisense drug development, pharmacokinetics, toxicity, target validation
MeSH terms
Animals, Humans, Oligonucleotides, Antisense, Biomedical Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review